An interventional study of PSMA PET in Prostatic Neoplasms, Metastases and PSMA-PET, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to male participants aged 40 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 5 that started in 2021, is one of 3 with no phase, and was the 1st registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18+ · Men only
Xijing Hospital · Sites in China
Ages 18–100 · Men only
Xijing Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–75 · Men only
Xijing Hospital · Sites in United States, China
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 40 Years to 90 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 190 across the 4 interventional studies, 1,000 across the 6 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
4 of the studies in Prostatic Neoplasms by Xijing Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06604130Xijing HospitalPlasma Exosome RNA to Diagnose Prostate Cancer | 2026-12-31 |
| NCT07492927Xijing HospitalPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer | 2026-12-31 |
| NCT06914427Xijing HospitalPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique | 2027-03-01 |
| NCT07553754Xijing HospitalPlasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Efficacy of 68Ga PSMA PET / CT in the diagnosis of lymph node metastasis in patients with prostate cancer: a single center prospective randomized controlled trial.
To identify and compare the diagnostic efficacy of 68Ga-PSMA PET/CT and mpMRI for lymph nodes in patients with newly diagnosed prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: PSMA PET
Diagnostic Test: PSMA PET
68Ga-PSMA PET
Diagnostic accuracy of PSMA PET and combined PSMA PET/MRI or PSMA PET/CT
To compare the diagnostic accuracy of PSMA PET and combined PSMA PET/MRI or PET/CT to that of the current standard multiparametric MRI, using histopathology as the gold standard.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Jun 2024, 36 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 36 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.